134 related articles for article (PubMed ID: 11697502)
1. Amifostine does not inhibit the toxic effects of anthracycline derivates or mitoxantrone on MDR tumor cell lines.
Michieli M; Michelutti A; Damiani D; Ermacora A; Masolini P; Stocchi R; Russo D
Leuk Lymphoma; 2001 Aug; 42(4):721-9. PubMed ID: 11697502
[TBL] [Abstract][Full Text] [Related]
2. Effect of amifostine on the cytotoxicity of daunorubicin and daunoxome in tumor and normal cells.
Michelutti A; Stocchi R; Candoni A; Tiribelli M; Calistri E; Russo D; Fanin R; Damiani D
Cancer Chemother Pharmacol; 2006 Apr; 57(4):517-24. PubMed ID: 16001170
[TBL] [Abstract][Full Text] [Related]
3. Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro.
Fulda S; Oster W; Berthold F
Anticancer Drugs; 1997 Jan; 8(1):34-41. PubMed ID: 9147609
[TBL] [Abstract][Full Text] [Related]
4. Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties.
Jekerle V; Klinkhammer W; Reilly RM; Piquette-Miller M; Wiese M
Cancer Chemother Pharmacol; 2007 Jan; 59(1):61-9. PubMed ID: 16636798
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
6. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.
Minderman H; O'Loughlin KL; Pendyala L; Baer MR
Clin Cancer Res; 2004 Mar; 10(5):1826-34. PubMed ID: 15014037
[TBL] [Abstract][Full Text] [Related]
7. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity.
List AF; Heaton R; Glinsmann-Gibson B; Capizzi RL
Semin Oncol; 1996 Aug; 23(4 Suppl 8):58-63. PubMed ID: 8783669
[TBL] [Abstract][Full Text] [Related]
8. Cytoprotection by WR-1065, the active form of amifostine, is independent of p53 status in human malignant glioma cell lines.
Kataoka Y; Murley JS; Patel R; Grdina DJ
Int J Radiat Biol; 2000 May; 76(5):633-9. PubMed ID: 10866285
[TBL] [Abstract][Full Text] [Related]
9. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):3-21. PubMed ID: 10348255
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporin A is a broad-spectrum multidrug resistance modulator.
Qadir M; O'Loughlin KL; Fricke SM; Williamson NA; Greco WR; Minderman H; Baer MR
Clin Cancer Res; 2005 Mar; 11(6):2320-6. PubMed ID: 15788683
[TBL] [Abstract][Full Text] [Related]
11. Cardioprotection of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR-1065, in vitro.
Dorr RT; Lagel K; McLean S
Eur J Cancer; 1996; 32A Suppl 4():S21-5. PubMed ID: 8976818
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia.
Michieli M; Damiani D; Ermacora A; Geromin A; Michelutti A; Masolini P; Baccarani M
Br J Haematol; 2000 Mar; 108(4):703-9. PubMed ID: 10792272
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of fotemustine (Muphoran) cytotoxicity by amifostine in malignant melanoma cell lines.
Merlin JL; Marchal S; Ramacci C; Berlion M; Poullain MG
Anticancer Drugs; 2002 Feb; 13(2):141-7. PubMed ID: 11901306
[TBL] [Abstract][Full Text] [Related]
15. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
16. Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines.
Laurençot CM; Scheffer GL; Scheper RJ; Shoemaker RH
Int J Cancer; 1997 Sep; 72(6):1021-6. PubMed ID: 9378536
[TBL] [Abstract][Full Text] [Related]
17. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
Roovers DJ; van Vliet M; Bloem AC; Lokhorst HM
Leuk Res; 1999 Jun; 23(6):539-48. PubMed ID: 10374847
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells.
Marbeuf-Gueye C; Broxterman HJ; Dubru F; Priebe W; Garnier-Suillerot A
Mol Pharmacol; 1998 Jan; 53(1):141-7. PubMed ID: 9443942
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications.
Michieli M; Damiani D; Ermacora A; Masolini P; Raspadori D; Visani G; Scheper RJ; Baccarani M
Br J Haematol; 1999 Feb; 104(2):328-35. PubMed ID: 10050716
[TBL] [Abstract][Full Text] [Related]
20. [Modulation of human small cell lung cancer cell line GLC4/ADR multidrug resistance in the inhibition of multidrug resistance-associated protein and its antisense].
Peng X; Feng F; Zhang W
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):355-8. PubMed ID: 11810759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
